专利检索 ap:("PFIZER INC.") AND inv:"Christoph Wolfgang Zapf" 第 1 页

1.

发明申请
Bruton's Tyrosine Kinase Inhibitors 审中-公开

公开(公告)号：US20190202798A1

公开(公告)日：2019-07-04

申请号：US16296319

申请日：2019-03-08

申请人： Pfizer Inc.

发明人： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt

IPC分类号： C07D401/04

摘要： Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

2.

发明申请
RORC2 INHIBITORS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20190144429A1

公开(公告)日：2019-05-16

申请号：US16261689

申请日：2019-01-30

申请人： Pfizer Inc.

发明人： Mark Edward Schnute , Gõran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones

IPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D403/04 , C07D487/04 , C07D471/04 , C07D417/14 , C07D413/04 , C07D407/14 , C07D401/04 , A61K31/5355 , A61K31/519 , A61K31/506 , A61K31/497 , A61K31/454

摘要： The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

3.

发明授权
Bruton's tyrosine kinase inhibitors 有权

公开(公告)号：US10815213B2

公开(公告)日：2020-10-27

申请号：US16296319

申请日：2019-03-08

申请人： Pfizer Inc.

发明人： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt

IPC分类号： C07D401/04 , C07D401/14 , A61K31/4155 , A61K31/454 , A61P29/00 , A61P35/00

摘要： Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

4.

发明授权
Bicyclic-fused heteroaryl or aryl compounds 有权

公开(公告)号：US10793579B2

公开(公告)日：2020-10-06

申请号：US16411679

申请日：2019-05-14

申请人： Pfizer Inc.

发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny

IPC分类号： C07D401/14 , A61K31/47 , A61K31/4709 , A61K31/4725 , C07D491/056 , C07F7/18 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

5.

发明申请
Bicyclic-Fused Heteroaryl or Aryl Compounds 审中-公开

公开(公告)号：US20180127432A1

公开(公告)日：2018-05-10

申请号：US15862691

申请日：2018-01-05

申请人： Pfizer Inc.

发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny

IPC分类号： C07D491/056 , C07D239/88 , C07D239/86 , C07D263/24 , C07D207/267 , A61K31/40 , C07D207/08 , C07F7/18 , C07D209/52 , C07D498/04 , C07D207/273 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D407/14 , C07D215/48 , C07D207/26 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61K31/4015

CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

6.

发明申请
Bruton's Tyrosine Kinase Inhibitors 审中-公开

公开(公告)号：US20170283393A1

公开(公告)日：2017-10-05

申请号：US15624969

申请日：2017-06-16

申请人： Pfizer Inc.

发明人： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt

IPC分类号： C07D401/04

CPC分类号： C07D401/04

摘要： Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

7.

发明申请
Bicyclic-Fused Heteroaryl or Aryl Compounds 审中-公开
标题翻译：双环稠合杂芳基或芳基化合物

公开(公告)号：US20160347760A1

公开(公告)日：2016-12-01

申请号：US15232892

申请日：2016-08-10

申请人： Pfizer Inc.

发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny

IPC分类号： C07D491/056 , A61K31/4709 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/267 , A61K31/4015 , C07D207/08 , A61K31/40 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , A61K45/06 , C07D401/12

CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 如说明书中所定义。还公开了相应的药物组合物，治疗方法，合成方法和中间体。

8.

发明授权
Bicyclic-fused heteroaryl or aryl compounds 有权
标题翻译：双环稠合的杂芳基或芳基化合物

公开(公告)号：US09458168B2

公开(公告)日：2016-10-04

申请号：US14678114

申请日：2015-04-03

申请人： Pfizer Inc.

发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Richard Vargas , Michael Dennis Lowe , Akshay Patny

IPC分类号： C07D207/26 , C07D401/12 , A61K31/44 , C07D491/056 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D215/48 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , C07F7/18

CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

9.

发明申请
Bruton's Tyrosine Kinase Inhibitors 审中-公开
标题翻译： Bruton的酪氨酸激酶抑制剂

公开(公告)号：US20150291554A1

公开(公告)日：2015-10-15

申请号：US14439478

申请日：2013-11-01

申请人： PFIZER INC.

发明人： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt

IPC分类号： C07D401/04

CPC分类号： C07D401/04

摘要： Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

摘要翻译： 本文公开的是与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。公开了制备化合物的方法。还公开了包含化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫性疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症。